AstraZeneca PLC said sales of its Covid-19 vaccine -- which it has promised to sell initially without profit -- haven't kept up with its costs, resulting in a hit to earnings and a warning the vaccine effort could continue to affect margins.
The drug giant's booked $275 million in revenue in the first three months of the year from sales of its Covid-19 vaccine, developed in partnership with the University of Oxford. The company delivered 68 million doses globally during the first quarter, far short of targets.
In Europe, AstraZeneca shortfalls totaling tens of millions of doses have inflamed political tensions. This week, the European Union sued the company, alleging failure to satisfy its vaccine contract with the bloc. AstraZeneca has said it is working to catch up with supply pledges.
Most of AstraZeneca's vaccine sales revenue in the quarter, $224 million, came from Europe, with $43 million in sales to emerging-markets countries. The numbers pale in comparison with multibillion-dollar sales forecasts of other vaccine makers including Pfizer Inc. and Moderna Inc.
For AstraZeneca, initially at least, the vaccine effort was a drain on earnings during an otherwise strong quarter. Costs from the effort shaved 3 cents off its per-share earnings for the quarter. Earnings per share came in at $1.18 in the quarter, versus 59 cents in the comparable quarter in 2020.
The company said it cost money to provide "equitable supply" of the vaccine at no profit, resulting in a "significant impact" on overall profit margins. Gross profit margins declined 3 percentage points in the quarter, to 74.6%.
"These variations in gross margin performance between quarters can be expected to continue," AstraZeneca said.
The British-Swedish drugmaker also said Friday it plans to apply to the U.S. Food and Drug Administration for authorization for the vaccine in coming weeks.
AstraZeneca's U.S. rollout plans have faced prolonged delays, after early estimates that the shot might be available in late 2020. The drugmaker said in March this year it would apply for FDA review by mid-April. The Wall Street Journal reported Thursday that AstraZeneca had told U.S. officials in recent days it might need until mid-May to finish its application.
The company has struggled to pull together the full data required for the report, which includes efficacy and safety statistics from almost four months of vaccinations in the U.K., plus data from large-scale U.S. and U.K. human trials, The Journal reported.
Overall first-quarter profit was $1.56 billion, roughly double a year ago, on increased revenue of $7.3 billion. A key benchmark, product sales, increased 15% on strong performance of core cancer drugs and new products in the company's pipeline.
Last year, the company doubled its full-year profit and struck a $39 billion deal to buy Boston-based Alexion Pharmaceuticals Inc., a maker of rare-disease drugs and therapies. But public attention has been heavily focused on the Covid-19 vaccine AstraZeneca brought to market in January, when the first mass vaccinations using the shot took place in the U.K. It is now in use in more than 100 countries.
The vaccine effort has faced a series of hurdles, from confusing clinical-trial results and production delays to questions about the shot's precise efficacy and rare blood-clotting problems among a small percentage of people post-vaccination.
Still, it is a major focus of global hopes for curbing the pandemic, especially among developing countries with less access to more expensive vaccines bought up by wealthier countries. AstraZeneca said the company, together with the Serum Institute of India, has delivered more than 48 million doses to a global funding initiative known as Covax focused on supplying shots to less-wealthy countries.
AstraZeneca reiterated its full-year outlook for total revenue increasing by a low-teens percentage, and core earnings per share rising to $5.00 from $4.00, all at constant exchange rates. The guidance doesn't incorporate revenue or profit impact from Covid-19 vaccine sales or the proposed Alexion acquisition.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.